Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new […]
Sunrun Prices $230 million Senior Securitization of Residential Solar & Battery Systems
SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), the nation’s leading provider of clean energy as a […]
Landstar to Release First Quarter Results on Wednesday, April 24, 2024
JACKSONVILLE, Fla., April 10, 2024 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ:LSTR), announced today it will release its 2024 first […]
Gilat Received Approximately $5 Million for Providing Services to a Leading LATAM Service Provider
PETAH TIKVA, Israel, April 10, 2024 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader […]
APA Corporation Provides First-Quarter 2024 Supplemental Information and Schedules Results Conference Call for May 2 at 10 a.m. Central Time
HOUSTON, April 10, 2024 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) today provided supplemental information regarding certain first-quarter 2024 financial […]
Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing […]
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for […]
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused […]
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab HB-200 program receives […]
Colliers adds market leader in Philadelphia
TORONTO and PHILADELPHIA, April 10, 2024 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management firm Colliers (NASDAQ and […]
